---
title: Construction of Gynecological Tumor Organoids
nct_id: NCT06155370
overall_status: UNKNOWN
sponsor: Peking Union Medical College Hospital
study_type: OBSERVATIONAL
primary_condition: Gynecologic Cancer
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06155370.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06155370"
ct_last_update_post_date: 2023-12-04
last_seen_at: "2026-05-12T07:04:40.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Construction of Gynecological Tumor Organoids

**NCT ID:** [NCT06155370](https://clinicaltrials.gov/study/NCT06155370)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Peking Union Medical College Hospital
- **Conditions:** Gynecologic Cancer, Organoid
- **Start Date:** 2023-12-01
- **Completion Date:** 2024-12-01
- **CT.gov Last Update:** 2023-12-04

## Brief Summary

This study focuses on the construction of a biological sample library for organoids and tumor tissues in gynecological tumors.

## Detailed Description

Explore the construction and maintenance of a large-scale queue of gynecological tumor organoids. Beijing Daxiang Technology Co., Ltd. provides corresponding technical support and chip design. Gynecological oncology center provides tumor samples, clinical information, and pathological support, and biological sample library provides technical support, storage space, and quality management.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** FEMALE

```
Inclusion Criteria:

1. Age of 18 or older, an informed consent form is provided;
2. The preoperative tumor burden assessment and intraoperative researcher team believe that sampling is feasible;
3. Having relevant requirements for sample library storage;
4. Surgical treatment at Peking Union Medical College Hospital.

Exclusion Criteria:

1. Unable to meet all inclusion criteria;
2. The research team considers any situations or considerations that may hinder normal pathological assessment.
```

## Arms

- **cohort of cervical cancer organoids** — organoids derived from cervical cancer
- **cohort of endometrial cancer organoids** — organoids derived from endometrial cancer
- **cohort of ovarian cancer organoids** — organoids derived from ovarian cancer
- **cohort of vulva cancer organoids** — organoids derived from vulva cancer
- **cohort of vaginal cancer organoids** — organoids derived from vaginal cancer
- **cohort of gestational trophoblastic tumor organoids** — organoids derived from gestational trophoblastic tumor

## Interventions

- **construction of organoids from gynecological tumor** (OTHER) — organoids construction

## Primary Outcomes

- **Construction of BioBank** _(time frame: one year)_ — BioBank including organoids banks, tissue banks, PDX banks, immune cell banks, and primary banks from other tissue sources

## Secondary Outcomes

- **Drug sensitivity detection based on organoids banks** _(time frame: one year)_
- **Exploring the molecular mechanism based on organoids banks** _(time frame: one year)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06155370.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06155370*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*